Guide

What happens after a BIMO inspection

After a BIMO inspection of a clinical investigator closes, the steps run in a set order: the inspector presents any observations on a Form FDA 483, the clinical investigator may respond, the reviewing center classifies the inspection NAI, VAI or OAI, and — for a small share of inspections — FDA acts, with a warning letter or disqualification proceedings. The sponsor of the trial is not typically told at any of these steps; the one exception is a disqualification.

FDA inspection flow chart

The sequence, step by step

1. The closing meeting. The inspector ends the visit by meeting with the clinical investigator. If the inspector observed conditions that may constitute violations, they are listed on a Form FDA 483 and discussed there. The observations are the inspector’s; they are not yet FDA’s position. Many inspections close with no 483 at all.

2. The response. The clinical investigator may respond to a 483 in writing. FDA’s practice is to consider a response received within 15 business days before deciding what action, if any, to take. A response is not mandatory, but submitting a response shows FDA that the inspection findings are being taken seriously, and a thorough one with corrective actions can affect what follows.

3. The inspection report. The inspector writes an establishment inspection report: what was examined, what was found, and how the clinical investigator answered at the time. The report, the 483 and any response go to the reviewing center — for drug and biologic trials, CDER or CBER.

4. The classification. The center, not the inspector, classifies the inspection: No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI), the most serious inspection classification FDA assigns. FDA classifies an inspection weeks to months after it closes, and a classification can be revised after the clinical investigator’s response is considered. What each one means: OAI, VAI and NAI.

5. FDA writes to the clinical investigator. Once the inspection is classified, FDA generally tells the clinical investigator the result in writing. For most inspections that is the end of the matter: an NAI needs nothing further, and a VAI leaves correction to the clinical investigator.

6. Further action, for a few. An OAI often leads eventually to a warning letter, FDA’s formal position that violations occurred, with a request for a written response, normally within 15 working days. Less formal routes are an untitled letter or an informal conference. Where FDA believes the violations were repeated or deliberate, or that false information was submitted, it may open disqualification with a NIDPOE letter, followed if unresolved by a NOOH letter. That is rare even among OAI inspections.

7. Closing the loop. A warning letter stays open until FDA is satisfied with the corrections; FDA may confirm that with a close-out letter, or with another inspection. A disqualification proceeding ends in no action, a consent agreement restricting the clinical investigator’s future research, or disqualification.

How long it takes

Longer than most people expect, and not on a fixed clock. The 483 is in hand the day the inspection closes. The classification follows weeks to months later. A warning letter, where there is one, generally comes months after the inspection it is based on. A disqualification proceeding, from the NIDPOE letter to a final decision, can span two or more years. At every point in that stretch the clinical investigator can be running other trials — and being considered for new ones.

Who is told what

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. Step by step:

The 483, the classification and any warning letter go to the clinical investigator. The clinical investigator is not required to report an inspection to the sponsor unless a quality agreement between them says so, and then possibly only for that sponsor’s trial. A large site often runs several sponsors’ trials at once, so the inspection may have concerned another study entirely.

Disqualification is the exception. When a clinical investigator is disqualified under 21 CFR 312.70, FDA notifies the sponsor of any investigation in which that clinical investigator was named, and the reviewing IRBs. By then the proceeding has usually been running for years.

None of this keeps a sponsor in the dark improperly; the inspection is of the clinical investigator, and the findings are theirs to answer. But the sponsor remains ultimately responsible for the quality and integrity of the trial data, and findings at a site may lead to scrutiny of the sponsor’s own compliance. More on the duties and the gap: sponsor responsibilities for clinical investigators.

When the inspection reaches the FDA record

What enters the FDA inspection record is the inspection with its classification and the findings FDA cited — the cited regulation and FDA’s own short description of each. Because classification takes weeks to months, an inspection that closed recently may not be on the record yet, and a record that was clear at site selection can change during the trial. A warning letter, a NIDPOE letter or a debarment arrives through separate datasets and documents that do not share identifiers, which is what makes one clinical investigator’s full history hard to assemble. Clinical Precedent assembles it into one record per clinical investigator, site, CRO and IRB, and updates it whenever new FDA information is available. What that record contains: clinical investigator inspection history.

What a sponsor does with it

For a candidate site, an inspection on the record is a read-the-findings situation, not a checkbox: what was cited, how long ago, whether it escalated, and how the site answered. The options are the usual three: ask the site for their responses and corrective action plans, visit the site before signing to perform your own evaluation of its compliance position, or choose a site without this history. For a site already running the sponsor’s trial, 21 CFR 312.56 frames the choice: secure compliance, or end the clinical investigator’s participation. How the record fits the selection decision: clinical investigator vetting and clinical investigator selection.

Questions this page answers

What happens after a BIMO inspection?

The inspector presents any observations on a Form FDA 483 at the closing meeting, and the clinical investigator may respond in writing. The inspector’s report, the 483 and the response go to the reviewing center, which classifies the inspection NAI, VAI or OAI weeks to months later. For a small share of inspections FDA then acts, most often with a warning letter.

How long does it take from a BIMO inspection to a warning letter?

There is no fixed clock. Any Form FDA 483 is issued the day the inspection closes, the classification follows weeks to months later, and a warning letter, where there is one, generally comes months after the inspection it is based on. A disqualification proceeding can span two or more years. Until an inspection is classified it may not appear on the FDA record at all.

Does every Form FDA 483 lead to a warning letter?

No. Most 483s lead to no further action. A warning letter can come later, from the center, if FDA’s review indicates that serious violations have occurred, and it is issued generally after an OAI classification. An inspection can end with a 483 and be classified NAI.

Is the sponsor told the result of a clinical investigator inspection?

Not typically. FDA sends inspection findings to the clinical investigator, not typically to the sponsor, and the clinical investigator is not required to report an inspection to the sponsor unless a quality agreement between them says so. The exception is disqualification, when FDA notifies the sponsor of any investigation the clinical investigator was named in.

What can a sponsor do when a site it is considering was inspected?

Read what FDA cited and when, then choose among three options: ask the site for their responses and corrective action plans, visit the site before signing to perform your own evaluation of its compliance position, or choose a site without this history. A history of NAI inspections is a positive fact worth recording; it is a different answer from never inspected.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.